25 results on '"Sun, Tao"'
Search Results
2. Effect and Mechanism of Rapamycin on Cognitive Deficits in Animal Models of Alzheimer's Disease: A Systematic Review and Meta-analysis of Preclinical Studies.
- Author
-
Cai, Jie, Xie, Danni, Kong, Fanjing, Zhai, Zhenwei, Zhu, Zhishan, Zhao, Yanru, Xu, Ying, and Sun, Tao
- Subjects
ALZHEIMER'S disease ,RAPAMYCIN ,ANIMAL models in research ,MEMORY disorders ,TRANSGENIC animals ,ANIMAL-assisted therapy - Abstract
Background: Alzheimer's disease (AD), the most common form of dementia, remains long-term and challenging to diagnose. Furthermore, there is currently no medication to completely cure AD patients. Rapamycin has been clinically demonstrated to postpone the aging process in mice and improve learning and memory abilities in animal models of AD. Therefore, rapamycin has the potential to be significant in the discovery and development of drugs for AD patients. Objective: The main objective of this systematic review and meta-analysis was to investigate the effects and mechanisms of rapamycin on animal models of AD by examining behavioral indicators and pathological features. Methods: Six databases were searched and 4,277 articles were retrieved. In conclusion, 13 studies were included according to predefined criteria. Three authors independently judged the selected literature and methodological quality. Use of subgroup analyses to explore potential mechanistic effects of rapamycin interventions: animal models of AD, specific types of transgenic animal models, dosage, and periodicity of administration. Results: The results of Morris Water Maze (MWM) behavioral test showed that escape latency was shortened by 15.60 seconds with rapamycin therapy, indicating that learning ability was enhanced in AD mice; and the number of traversed platforms was increased by 1.53 times, indicating that the improved memory ability significantly corrected the memory deficits. CONCLUSIONS: Rapamycin therapy reduced age-related plaque deposition by decreasing AβPP production and down-regulating β-secretase and γ-secretase activities, furthermore increased amyloid-β clearance by promoting autophagy, as well as reduced tau hyperphosphorylation by up-regulating insulin-degrading enzyme levels. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Effect and Potential Mechanism of Immunotherapy on Cognitive Deficits in Animal Models of Alzheimer's Disease: A Systematic Review and Meta-Analysis.
- Author
-
Zhai, Zhenwei, Kong, Fanjing, Zhu, Zhishan, Dai, Jingyi, Cai, Jie, Xie, Danni, Shen, Yuzhao, Xu, Ying, and Sun, Tao
- Abstract
• What is the primary question addressed by this study? This study explored whether different immunological approaches and animal models have an effect on the improvement of cognitive dysfunction in Alzheimer's disease (AD) and the potential mechanism of immunotherapy to ameliorate cognitive dysfunction in AD animal models? • What is the main finding of this study? Active and passive immunization could markedly ameliorate learning and memory impairment in 3 × Tg AD animal models, and active immunization could ameliorate the learning and memory ability of the APPswe/PS1ΔE9 AD animal model compared to the control group. Cognitive dysfunction was ameliorated by immunotherapy, which might mainly be via reducing Aβ40, Aβ42, and Tau levels, as well as increasing IL-4 levels. • What is the meaning of the finding? Immunotherapy may be a potential treatment to alleviate symptoms in animal models of AD. Meanwhile, this Systematic Review and Meta-Analysis may also provide theoretical insight into the clinical translation of immunotherapy. Immunotherapy has been reported to ameliorate Alzheimer's disease (AD) in the animal model; however, the immunologic approaches and mechanisms have not been specifically described. Thus, the systematic review and meta-analysis were conducted to explore the effect and potential mechanism of immunotherapy on AD animal experiments based on behavioral indicators. According to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses and the Cochrane Collaboration guidelines and the inclusion/exclusion criteria of immunotherapy in animal studies, 15 studies were systematically reviewed after extraction from a collected database of 3,742 publications. Finally, the effect and mechanism of immunotherapy on AD models were described by performing multiple subgroup analyses. After immunotherapy, the escape latency was reduced by 18.15 seconds and the number of crossings over the platform location was increased by 1.60 times in the Morris Water Maze. Furthermore, compared to the control group, active and passive immunization could markedly ameliorate learning and memory impairment in 3 × Tg AD animal models, and active immunization could ameliorate the learning and memory ability of the APPswe/PS1ΔE9 AD animal model. Meanwhile, it could be speculated that cognitive dysfunction was improved by immunotherapy, perhaps mainly via reducing Aβ40, Aβ42, and Tau levels, as well as increasing IL-4 levels. Immunotherapy significantly ameliorated the cognitive dysfunction of AD animal models by assessing behavioral indicators. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Serum Bile Acids Improve Prediction of Alzheimer's Progression in a Sex‐Dependent Manner.
- Author
-
Chen, Tianlu, Wang, Lu, Xie, Guoxiang, Kristal, Bruce S., Zheng, Xiaojiao, Sun, Tao, Arnold, Matthias, Louie, Gregory, Li, Mengci, Wu, Lirong, Mahmoudiandehkordi, Siamak, Sniatynski, Matthew J., Borkowski, Kamil, Guo, Qihao, Kuang, Junliang, Wang, Jieyi, Nho, Kwangsik, Ren, Zhenxing, Kueider‐Paisley, Alexandra, and Blach, Colette
- Subjects
ALZHEIMER'S disease ,BILE acids ,RECEIVER operating characteristic curves ,MILD cognitive impairment ,NEUROFIBRILLARY tangles - Abstract
Sex disparities in serum bile acid (BA) levels and Alzheimer's disease (AD) prevalence have been established. However, the precise link between changes in serum BAs and AD development remains elusive. Here, authors quantitatively determined 33 serum BAs and 58 BA features in 4 219 samples collected from 1 180 participants from the Alzheimer's Disease Neuroimaging Initiative. The findings revealed that these BA features exhibited significant correlations with clinical stages, encompassing cognitively normal (CN), early and late mild cognitive impairment, and AD, as well as cognitive performance. Importantly, these associations are more pronounced in men than women. Among participants with progressive disease stages (n = 660), BAs underwent early changes in men, occurring before AD. By incorporating BA features into diagnostic and predictive models, positive enhancements are achieved for all models. The area under the receiver operating characteristic curve improved from 0.78 to 0.91 for men and from 0.76 to 0.83 for women for the differentiation of CN and AD. Additionally, the key findings are validated in a subset of participants (n = 578) with cerebrospinal fluid amyloid‐beta and tau levels. These findings underscore the role of BAs in AD progression, offering potential improvements in the accuracy of AD prediction. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. Knowledge domains and emerging trends of Genome-wide association studies in Alzheimer's disease: A bibliometric analysis and visualization study from 2002 to 2022.
- Author
-
Kong, Fanjing, Wu, Tianyu, Dai, Jingyi, Cai, Jie, Zhai, Zhenwei, Zhu, Zhishan, Xu, Ying, and Sun, Tao
- Subjects
GENOME-wide association studies ,ALZHEIMER'S disease ,BIBLIOMETRICS ,DATA visualization ,NEURODEGENERATION - Abstract
Objectives: Alzheimer's disease (AD) is a neurodegenerative disorder characterized by a progressive decline in cognitive and behavioral function. Studies have shown that genetic factors are one of the main causes of AD risk. genome-wide association study (GWAS), as a novel and effective tool for studying the genetic risk of diseases, has attracted attention from researchers in recent years and a large number of studies have been conducted. This study aims to summarize the literature on GWAS in AD by bibliometric methods, analyze the current status, research hotspots and future trends in this field. Methods: We retrieved articles on GWAS in AD published between 2002 and 2022 from Web of Science. CiteSpace and VOSviewer software were applied to analyze the articles for the number of articles published, countries/regions and institutions of publication, authors and cited authors, highly cited literature, and research hotspots. Results: We retrieved a total of 2,751 articles. The United States had the highest number of publications in this field, and Columbia University was the institution with the most published articles. The identification of AD-related susceptibility genes and their effects on AD is one of the current research hotspots. Numerous risk genes have been identified, among which APOE, CLU, CD2AP, CD33, EPHA1, PICALM, CR1, ABCA7 and TREM2 are the current genes of interest. In addition, risk prediction for AD and research on other related diseases are also popular research directions in this field. Conclusion: This study conducted a comprehensive analysis of GWAS in AD and identified the current research hotspots and research trends. In addition, we also pointed out the shortcomings of current research and suggested future research directions. This study can provide researchers with information about the knowledge structure and emerging trends in the field of GWAS in AD and provide guidance for future research. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Impact of TRPV1 on Pathogenesis and Therapy of Neurodegenerative Diseases.
- Author
-
Wang, Wenxin and Sun, Tao
- Subjects
- *
TRP channels , *TRPV cation channels , *NEURODEGENERATION , *ALZHEIMER'S disease , *PARKINSON'S disease , *PATHOGENESIS - Abstract
Transient receptor potential vanilloid 1 (TRPV1) is a transmembrane and non-selective cation channel protein, which can be activated by various physical and chemical stimuli. Recent studies have shown the strong pathogenetic associations of TRPV1 with neurodegenerative diseases (NDs), in particular Alzheimer's disease (AD), Parkinson's disease (PD) and multiple sclerosis (MS) via regulating neuroinflammation. Therapeutic effects of TRPV1 agonists and antagonists on the treatment of AD and PD in animal models also are emerging. We here summarize the current understanding of TRPV1's effects and its agonists and antagonists as a therapeutic means in neurodegenerative diseases, and highlight future treatment strategies using natural TRPV1 agonists. Developing new targets and applying natural products are becoming a promising direction in the treatment of chronic disorders, especially neurodegenerative diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Moschus ameliorates glutamate-induced cellular damage by regulating autophagy and apoptosis pathway.
- Author
-
Xie, Danni, Song, Caiyou, Qin, Tao, Zhai, Zhenwei, Cai, Jie, Dai, Jingyi, Sun, Tao, and Xu, Ying
- Subjects
AUTOPHAGY ,B cells ,ALZHEIMER'S disease ,CELL survival ,APOPTOSIS ,CHINESE medicine ,CEREBROVASCULAR disease - Abstract
Alzheimer's disease (AD), a neurodegenerative disorder, causes short-term memory and cognition declines. It is estimated that one in three elderly people die from AD or other dementias. Chinese herbal medicine as a potential drug for treating AD has gained growing interest from many researchers. Moschus, a rare and valuable traditional Chinese animal medicine, was originally documented in Shennong Ben Cao Jing and recognized for its properties of reviving consciousness/resuscitation. Additionally, Moschus has the efficacy of "regulation of menstruation with blood activation, relief of swelling and pain" and is used for treating unconsciousness, stroke, coma, and cerebrovascular diseases. However, it is uncertain whether Moschus has any protective effect on AD patients. We explored whether Moschus could protect glutamate (Glu)-induced PC12 cells from cellular injury and preliminarily explored their related action mechanisms. The chemical compounds of Moschus were analyzed and identified by GC–MS. The Glu-induced differentiated PC12 cell model was thought to be the common AD cellular model. The study aims to preliminarily investigate the intervention effect of Moschus on Glu-induced PC12 cell damage as well as their related action mechanisms. Cell viability, lactate dehydrogenase (LDH), mitochondrial reactive oxygen species, mitochondrial membrane potential (MMP), cell apoptosis, autophagic vacuoles, autolysosomes or autophagosomes, proteins related to apoptosis, and the proteins related to autophagy were examined and analyzed. Seventeen active compounds of the Moschus sample were identified based on GC–MS analysis. In comparison to the control group, Glu stimulation increased cell viability loss, LDH release, mitochondrial damage, loss of MMP, apoptosis rate, and the number of cells containing autophagic vacuoles, and autolysosomes or autophagosomes, while these results were decreased after the pretreatment with Moschus and 3-methyladenine (3-MA). Furthermore, Glu stimulation significantly increased cleaved caspase-3, Beclin1, and LC3II protein expression, and reduced B-cell lymphoma 2/BAX ratio and p62 protein expression, but these results were reversed after pretreatment of Moschus and 3-MA. Moschus has protective activity in Glu-induced PC12 cell injury, and the potential mechanism might involve the regulation of autophagy and apoptosis. Our study may promote research on Moschus in the field of neurodegenerative diseases, and Moschus may be considered as a potential therapeutic agent for AD. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. Neural network on interval‐censored data with application to the prediction of Alzheimer's disease.
- Author
-
Sun, Tao and Ding, Ying
- Subjects
- *
ALZHEIMER'S disease , *CENSORING (Statistics) , *GENETIC variation , *DISEASE progression , *GAS separation membranes , *GENOME-wide association studies , *PREDICTION models - Abstract
Alzheimer's disease (AD) is a progressive and polygenic disorder that affects millions of individuals each year. Given that there have been few effective treatments yet for AD, it is highly desirable to develop an accurate model to predict the full disease progression profile based on an individual's genetic characteristics for early prevention and clinical management. This work uses data composed of all four phases of the Alzheimer's Disease Neuroimaging Initiative (ADNI) study, including 1740 individuals with 8 million genetic variants. We tackle several challenges in this data, characterized by large‐scale genetic data, interval‐censored outcome due to intermittent assessments, and left truncation in one study phase (ADNIGO). Specifically, we first develop a semiparametric transformation model on interval‐censored and left‐truncated data and estimate parameters through a sieve approach. Then we propose a computationally efficient generalized score test to identify variants associated with AD progression. Next, we implement a novel neural network on interval‐censored data (NN‐IC) to construct a prediction model using top variants identified from the genome‐wide test. Comprehensive simulation studies show that the NN‐IC outperforms several existing methods in terms of prediction accuracy. Finally, we apply the NN‐IC to the full ADNI data and successfully identify subgroups with differential progression risk profiles. Data used in the preparation of this article were obtained from the ADNI database. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
9. β-Amyloid targeting nanodrug for neuron-specific delivery of nucleic acids in Alzheimer's disease mouse models.
- Author
-
Israel, Liron L., Sun, Tao, Braubach, Oliver, Cox, Alysia, Shatalova, Ekaterina S., Rashid, Harun-Mohammad, Galstyan, Anna, Grodzinski, Zachary, Song, Xue Ying, Chepurna, Oksana, Ljubimov, Vladimir A., Chiechi, Antonella, Sharma, Sachin, Phebus, Connor, Wang, Yizhou, Ljubimova, Julia Y., Black, Keith L., and Holler, Eggehard
- Subjects
- *
ALZHEIMER'S disease , *NUCLEIC acids , *CONJUGATED polymers , *BLOOD-brain barrier , *LABORATORY mice , *ANTISENSE RNA , *AMYLOID plaque - Abstract
Delivery of therapeutic substances into the brain poses a significant challenge in the treatment of neurological disorders. This is primarily due to the blood–brain barrier (BBB), which restricts access, alongside the limited stability and distribution of these agents within the brain tissue. Here we demonstrate an efficient delivery of microRNA (miRNA) and antisense RNA preferentially to neurons compared to astroglia in the brain of healthy and Alzheimer's disease mice, via disulfide-linked conjugation with poly(ß-L-malic acid-trileucine)-copolymer a biodegradable, amphiphilic, and multivalent platform. By conjugating a D-configured (D3)-peptide (vector) for specific targeting, highly efficient delivery across the BBB is achieved through the Low-Density Lipoprotein Receptor-Related Protein-1 (LRP-1) transcytosis pathway, amyloid beta (Aβ) peptides. Nanodrug distribution was determined by fluorescent labeling and analyzed by microscopy in neurons, astroglia, and in extracellular amyloid plaques typical for Alzheimer's disease. Whereas D-configured BBB-vectors can efficiently target neurons, L-configured (e.g., AP2-peptide) guided vector can only cross BBB but not seem to bind neurons. An analysis of post-injection fluorescence distribution, and RNA-seq followed by real-time PCR validation, confirmed a successful in vivo delivery of morpholino-miRNA-186 nanoconjugates into mouse brain. The size and fluorescence intensity of the intracellular nanodrug particulates were analyzed and verified by a competition with non-fluorescent conjugates. Differentially expressed genes (DEGs) from RNA-seq were identified in the nanodrug injected mice, and the changes of selected DEGs related to Alzheimer's disease were further validated by western blot and real-time PCR. Collectively, these results demonstrated that D3-peptide-conjugated nanopolymer drug is able to achieve neuron-selective delivery of miRNA and can serve as an efficient brain delivery vehicle in Alzheimer's disease (AD) mouse models. Graphical abstract: D peptides are used to facilitate polymeric nanodrugs containing nucleic acids to cross the BBB and preferentially target neurons or amyloid plaques in the Alzheimer's disease mouse brain. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
10. Genome-wide significant, replicated and functional risk variants for Alzheimer’s disease
- Author
-
Guo, Xiaoyun, Qiu, Wenying, Garcia-Milian, Rolando, Lin, Xiandong, Zhang, Yong, Cao, Yuping, Tan, Yunlong, Wang, Zhiren, Shi, Jing, Wang, Jijun, Liu, Dengtang, Song, Lisheng, Xu, Yifeng, Wang, Xiaoping, Liu, Na, Sun, Tao, Zheng, Jianming, Luo, Justine, Zhang, Huihao, Xu, Jianying, Kang, Longli, Ma, Chao, Wang, Kesheng, and Luo, Xingguang
- Published
- 2017
- Full Text
- View/download PDF
11. Neuroprotective effects of hawthorn leaf flavonoids in Aβ25–35‐induced Alzheimer's disease model.
- Author
-
Xu, Ying, Deng, Ting, Xie, Linjiang, Qin, Tao, and Sun, Tao
- Abstract
Alzheimer's disease (AD) is a progressive neurodegenerative disease characterized by β‐amyloid (Aβ) plaques, neurofibrillary tangles, neuronal cell loss, and oxidative stress. Further deposition of Aβ in the brain induces oxidative stress, neuroinflammation, and memory dysfunction. Hawthorn (Crataegus pinnatifida Bge.) leaf, a known traditional Chinese medicine, is commonly used for the treatment of hyperlipidemia, heart palpitations, forgetfulness, and tinnitus, and its main bioactive components are Hawthorn Leaf Flavonoids (HLF). In this study, we investigated the neuroprotective effects of the HLF on the Aβ25–35 (bilateral hippocampus injection) rat model of AD. The results showed that the oral administration of HLF at a dose of 50, 100, and 200 mg/kg for 30 days significantly ameliorated neuronal cell damage and memory deficits, and markedly increased the enzyme activities of superoxide dismutase and catalase, and the content of glutathione whereas it decreased the malondialdehyde content in the Aβ25–35 rat model of AD as well as suppressed the activation of astrocytes. In addition, HLF up‐regulated Nrf‐2, NQO‐1, and HO‐1 protein expressions. Also, it reduced neuroinflammation by inhibiting activation of astrocytes. In summary, these results indicated that HLF decreased the oxidative stress via activating Nrf‐2/antioxidant response element signaling pathways, and may suggest as a potential candidate for AD therapeutic agent. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
12. Acute Effects of Focused Ultrasound-Induced Blood-Brain Barrier Opening on Anti-Pyroglu3 Abeta Antibody Delivery and Immune Responses.
- Author
-
Bathini, Praveen, Sun, Tao, Schenk, Mathias, Schilling, Stephan, McDannold, Nathan J., and Lemere, Cynthia A.
- Subjects
- *
IMMUNOGLOBULINS , *IMMUNE response , *BLOOD-brain barrier , *ALZHEIMER'S disease , *AMYLOID plaque , *TRANSGENIC mice , *NEURODEGENERATION - Abstract
Alzheimer's Disease (AD) is a neurodegenerative disorder characterized by the accumulation of amyloid plaques and hyperphosphorylated tau in the brain. Currently, therapeutic agents targeting amyloid appear promising for AD, however, delivery to the CNS is limited due to the blood-brain-barrier (BBB). Focused ultrasound (FUS) is a method to induce a temporary opening of the BBB to enhance the delivery of therapeutic agents to the CNS. In this study, we evaluated the acute effects of FUS and whether the use of FUS-induced BBB opening enhances the delivery of 07/2a mAb, an anti-pyroglutamate-3 Aβ antibody, in aged 24 mo-old APP/PS1dE9 transgenic mice. FUS was performed either unilaterally or bilaterally with mAb infusion and the short-term effect was analyzed 4 h and 72 h post-treatment. Quantitative analysis by ELISA showed a 5–6-fold increase in 07/2a mAb levels in the brain at both time points and an increased brain-to-blood ratio of the antibody. Immunohistochemistry demonstrated an increase in IgG2a mAb detection particularly in the cortex, enhanced immunoreactivity of resident Iba1+ and phagocytic CD68+ microglial cells, and a transient increase in the infiltration of Ly6G+ immune cells. Cerebral microbleeds were not altered in the unilaterally or bilaterally sonicated hemispheres. Overall, this study shows the potential of FUS therapy for the enhanced delivery of CNS therapeutics. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
13. Identifying Mild Alzheimer's Disease With First 30-Min 11C-PiB PET Scan.
- Author
-
Shen, Chushu, Wang, Zhenguo, Chen, Hongzhao, Bai, Yan, Li, Xiaochen, Liang, Dong, Liu, Xin, Zheng, Hairong, Wang, Meiyun, Yang, Yongfeng, Wang, Haifeng, and Sun, Tao
- Subjects
BRAIN ,KRUSKAL-Wallis Test ,ALZHEIMER'S disease ,PREDICTIVE tests ,AMYLOIDOSIS ,RESEARCH evaluation ,MACHINE learning ,POSITRON emission tomography ,RADIATION doses ,LOGISTIC regression analysis ,RECEIVER operating characteristic curves ,SENSITIVITY & specificity (Statistics) ,DATA analysis software - Abstract
Introduction:
11 C-labeled Pittsburgh compound B (11 C-PiB) PET imaging can provide information for the diagnosis of Alzheimer's disease (AD) by quantifying the binding of PiB to β-amyloid deposition in the brain. Quantification index, such as standardized uptake value ratio (SUVR) and distribution volume ratio (DVR), has been exploited to effectively distinguish between healthy and subjects with AD. However, these measures require a long wait/scan time, as well as the selection of an optimal reference region. In this study, we propose an alternate measure named amyloid quantification index (AQI), which can be obtained with the first 30-min scan without the selection of the reference region. Methods:11 C-labeled Pittsburgh compound B PET scan data were obtained from the public dataset "OASIS-3". A total of 60 mild subjects with AD and 60 healthy controls were included, with 50 used for training and 10 used for testing in each group. The proposed measure AQI combines information of clearance rate and mid-phase PIB retention in featured brain regions from the first 30-min scan. For each subject in the training set, AQI, SUVR, and DVR were calculated and used for classification by the logistic regression classifier. The receiver operating characteristic (ROC) analysis was performed to evaluate the performance of these measures. Accuracy, sensitivity, and specificity were reported. The Kruskal–Wallis test and effect size were also performed and evaluated for all measures. Then, the performance of three measures was further validated on the testing set using the same method. The correlations between these measures and clinical MMSE and CDR-SOB scores were analyzed. Results: The Kruskal–Wallis test suggested that AQI, SUVR, and DVR can all differentiate between the healthy and subjects with mild AD (p < 0.001). For the training set, ROC analysis showed that AQI achieved the best classification performance with an accuracy rate of 0.93, higher than 0.88 for SUVR and 0.89 for DVR. The effect size of AQI, SUVR, and DVR were 2.35, 2.12, and 2.06, respectively, indicating that AQI was the most effective among these measures. For the testing set, all three measures achieved less superior performance, while AQI still performed the best with the highest accuracy of 0.85. Some false-negative cases with below-threshold SUVR and DVR values were correctly identified using AQI. All three measures showed significant and comparable correlations with clinical scores (p < 0.01). Conclusion: Amyloid quantification index combines early-phase kinetic information and a certain degree of β-amyloid deposition, and can provide a better differentiating performance using the data from the first 30-min dynamic scan. Moreover, it was shown that clinically indistinguishable AD cases regarding PiB retention potentially can be correctly identified. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
14. Focused ultrasound with anti-pGlu3 Aβ enhances efficacy in Alzheimer's disease-like mice via recruitment of peripheral immune cells.
- Author
-
Sun, Tao, Shi, Qiaoqiao, Zhang, Yongzhi, Power, Chanikarn, Hoesch, Camilla, Antonelli, Shawna, Schroeder, Maren K., Caldarone, Barbara J., Taudte, Nadine, Schenk, Mathias, Hettmann, Thore, Schilling, Stephan, McDannold, Nathan J., and Lemere, Cynthia A.
- Subjects
- *
MICROBUBBLE diagnosis , *ULTRASONIC imaging , *COGNITIVE ability , *BLOOD-brain barrier , *MICE , *AMYLOID plaque , *ALZHEIMER'S disease - Abstract
Pyroglutamate-3 amyloid-β (pGlu3 Aβ) is an N-terminally modified, pathogenic form of amyloid-β that is present in cerebral amyloid plaques and vascular deposits. Here, we used focused ultrasound (FUS) with microbubbles to enhance the intravenous delivery of an Fc-competent anti-pGlu3 Aβ monoclonal antibody, 07/2a mAb, across the blood brain barrier (BBB) in an attempt to improve Aβ removal and memory in aged APP/PS1dE9 mice, an Alzheimer's disease (AD)-like model of amyloidogenesis. First, we demonstrated that bilateral hippocampal FUS-BBB disruption (FUS-BBBD) led to a 5.5-fold increase of 07/2a mAb delivery to the brains compared to non-sonicated mice 72 h following a single treatment. Then, we determined that three weekly treatments with 07/2a mAb alone improved spatial learning and memory in aged, plaque-rich APP/PS1dE9 mice, and that this improvement occurred faster and in a higher percentage of animals when combined with FUS-BBBD. Mice given the combination treatment had reduced hippocampal plaque burden compared to PBS-treated controls. Furthermore, synaptic protein levels were higher in hippocampal synaptosomes from mice given the combination treatment compared to sham controls, and there were more CA3 synaptic puncta labeled in the APP/PS1dE9 mice given the combination treatment compared to those given mAb alone. Plaque-associated microglia were present in the hippocampi of APP/PS1dE9 mice treated with 07/2a mAb with and without FUS-BBBD. However, we discovered that plaque-associated Ly6G+ monocytes were only present in the hippocampi of APP/PS1dE9 mice that were given FUS-BBBD alone or even more so, the combination treatment. Lastly, FUS-BBBD did not increase the incidence of microhemorrhage in mice with or without 07/2a mAb treatment. Our findings suggest that FUS is a useful tool to enhance delivery and efficacy of an anti-pGlu3 Aβ mAb for immunotherapy either via an additive effect or an independent mechanism. We revealed a potential novel mechanism wherein the combination of 07/2a mAb with FUS-BBBD led to greater monocyte infiltration and recruitment to plaques in this AD-like model. Overall, these effects resulted in greater plaque removal, sparing of synapses and improved cognitive function without causing overt damage, suggesting the possibility of FUS-BBBD as a noninvasive method to increase the therapeutic efficacy of drugs or biologics in AD patients. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
15. Analysis of the role of Purα in the pathogenesis of Alzheimer's disease based on RNA-seq and ChIP-seq.
- Author
-
Shi, Xiaoguang, Ren, Shuanglai, Zhang, Bingying, Guo, Shanshan, He, Wenxin, Yuan, Chengmin, Yang, Xiaofan, Ig-lzevbekhai, Kevin, Sun, Tao, Wang, Qinwen, and Cui, Jianqi
- Subjects
ALZHEIMER'S disease ,RNA sequencing ,DNA replication ,GENE expression ,CELLS - Abstract
Purine rich element binding protein A (Purα), encoded by the Purα gene, is an important transcriptional regulator that binds to DNA and RNA and is involved in processes such as DNA replication and RNA translation. Purα also plays an important role in the nervous system. To identify the function of Pura, we performed RNA sequence (RNA-seq) analysis of Purɑ-KO mouse hippocampal neuron cell line (HT22) to analyze the effect of Purα deletion on neuronal expression profiles. And combined with ChIP-seq analysis to explore the mechanism of Purα on gene regulation. In the end, totaly 656 differentially expressed genes between HT22 and Purα-KO HT22 cells have been found, which include 7 Alzheimer's disease (AD)-related genes and 5 Aβ clearance related genes. 47 genes were regulated by Purα directly, the evidence based on CHIP-seq, which include Insr, Mapt, Vldlr, Jag1, etc. Our study provides the important informations of Purα in neuro-development. The possible regulative effects of Purα on AD-related genes consist inthe direct and indirect pathways of Purα in the pathogenesis of AD. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
16. Electroacupuncture in the repair of spinal cord injury: inhibiting the Notch signaling pathway and promoting neural stem cell proliferation
- Author
-
Ning Zhao, Sun Tao, Jinghui Li, Hualin Yu, Xin Geng, and Yong Wang
- Subjects
Electroacupuncture ,medicine.medical_treatment ,notch signaling pathway ,proliferation ,Notch signaling pathway ,microglia ,Inflammation ,lcsh:RC346-429 ,neuroinflammation ,rosiglitazone ,Developmental Neuroscience ,Western blot ,real-time quantitative PCR ,medicine ,nerve regeneration ,Spinal cord injury ,lcsh:Neurology. Diseases of the nervous system ,neural stem cells ,dextromethorphan ,medicine.diagnostic_test ,tamoxifen ,business.industry ,auranofin ,neurodegeneration ,astrocytes ,spinal cord ,survival curve ,differentiation ,Spinal cord ,medicine.disease ,PP2 ,Neural stem cell ,electroacupuncture therapy ,medicine.anatomical_structure ,trauma ,Alzheimer′s disease ,inflammation ,regeneration ,Cancer research ,neuroprotection ,Src kinase ,Electroacupuncture Therapy ,medicine.symptom ,business ,neural regeneration ,Neuroscience ,Research Article ,western blot assay - Abstract
Electroacupuncture for the treatment of spinal cord injury has a good clinical curative effect, but the underlying mechanism is unclear. In our experiments, the spinal cord of adult Sprague-Dawley rats was clamped for 60 seconds. Dazhui (GV14) and Mingmen (GV4) acupoints of rats were subjected to electroacupuncture. Enzyme-linked immunosorbent assay revealed that the expression of serum inflammatory factors was apparently downregulated in rat models of spinal cord injury after electroacupuncture. Hematoxylin-eosin staining and immunohistochemistry results demonstrated that electroacupuncture contributed to the proliferation of neural stem cells in rat injured spinal cord, and suppressed their differentiation into astrocytes. Real-time quantitative PCR and western blot assays showed that electroacupuncture inhibited activation of the Notch signaling pathway induced by spinal cord injury. These findings indicate that electroacupuncture repaired the injured spinal cord by suppressing the Notch signaling pathway and promoting the proliferation of endogenous neural stem cells.
- Published
- 2015
17. Putative Roles of Plant-Derived Tannins in Neurodegenerative and Neuropsychiatry Disorders: An Updated Review.
- Author
-
Hussain, Ghulam, Huang, Jia, Rasul, Azhar, Anwar, Haseeb, Imran, Ali, Maqbool, Javeria, Razzaq, Aroona, Aziz, Nimra, Makhdoom, Ehtisham ul Haq, Konuk, Muhsin, Sun, Tao, and Andrade, Paula B.
- Subjects
TANNINS ,NEURODEGENERATION ,PARKINSON'S disease ,NEUROBEHAVIORAL disorders ,ALZHEIMER'S disease ,BOTANICAL chemistry - Abstract
Neurodegenerative and neuropsychiatric diseases are characterized by the structural and functional abnormalities of neurons in certain regions of the brain. These abnormalities, which can result in progressive neuronal degeneration and functional disability, are incurable to date. Although comprehensive efforts have been made to figure out effective therapies against these diseases, partial success has been achieved and complete functional recovery is still not a reality. At present, plants and plant-derived compounds are getting more attention because of a plethora of pharmacological properties, and they are proving to be a better and safer target as therapeutic interventions. This review aims to highlight the roles of tannins, 'the polyphenol phytochemicals', in tackling neurodegenerative diseases including Alzheimer's and Parkinson's diseases as well as neuropsychiatric disorders like depression. Among the multifarious pharmacological properties of tannins, anti-oxidative, anti-inflammatory, and anti-cholinesterase activities are emphasized more in terms of neuroprotection. The current review also throws light on mechanistic pathways by which various classes of tannins execute neuroprotective effects. Despite their beneficial properties, some harmful effects of tannins have also been elaborated. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
18. Microenvironment Remodeling Micelles for Alzheimer's Disease Therapy by Early Modulation of Activated Microglia.
- Author
-
Lu, Yifei, Guo, Zhongyuan, Zhang, Yujie, Li, Chao, Zhang, Yu, Guo, Qin, Chen, Qinjun, Chen, Xinli, He, Xi, Liu, Lisha, Ruan, Chunhui, Sun, Tao, Ji, Bin, Lu, Weigen, and Jiang, Chen
- Subjects
ALZHEIMER'S disease treatment ,MICROGLIA ,MICELLES - Abstract
Current strategies for Alzheimer's disease (AD) treatments focus on pathologies in the late stage of the disease progression. Poor clinical outcomes are displayed due to the irreversible damages caused by early microglia abnormality which triggers disease development before identical symptoms emerge. Based on the crosstalk between microglia and brain microenvironment, a reactive oxygen species (ROS)‐responsive polymeric micelle system (Ab‐PEG‐LysB/curcumin (APLB/CUR)) is reported to normalize the oxidative and inflammatory microenvironment and reeducate microglia from an early phase of AD. Through an β‐amyloid (Aβ) transportation‐mimicked pathway, the micelles can accumulate into the diseased regions and exert synergistic effects of polymer‐based ROS scavenging and cargo‐based Aβ inhibition upon microenvironment stimuli. This multitarget strategy exhibits gradual correction of the brain microenvironment, efficient neuroprotection, and microglia modulation, leading to decreased Aβ plaque burdens and consequently enhanced cognitive functions in APPswe/PSEN1dE9 model mice. The results indicate that microglia can be exploited as an early target for AD treatment and their states can be controlled via microenvironment modulation. A dual‐functional polymeric micelle system is designed to normalize the oxidative and inflammatory microenvironment and reeducate microglia from an early phase of Alzheimer's disease. Polymer‐based reactive oxygen species scavenging and cargo‐based β‐amyloid (Aβ) inhibition in response to the brain microenvironment can synergistically exert efficient neuroprotection and microglia modulation and lead to decreased Aβ plaque burdens and enhanced cognitive functions. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
19. Alzheimer's Disease: Microenvironment Remodeling Micelles for Alzheimer's Disease Therapy by Early Modulation of Activated Microglia (Adv. Sci. 4/2019).
- Author
-
Lu, Yifei, Guo, Zhongyuan, Zhang, Yujie, Li, Chao, Zhang, Yu, Guo, Qin, Chen, Qinjun, Chen, Xinli, He, Xi, Liu, Lisha, Ruan, Chunhui, Sun, Tao, Ji, Bin, Lu, Weigen, and Jiang, Chen
- Subjects
ALZHEIMER'S disease treatment ,COPOLYMER micelles ,MICROGLIA - Abstract
An Alzheimer's disease (AD) brain is featured with the oxidative and inflammatory microenvironment caused by overactivated microglia. In article number 1801586, Chen Jiang and co‐workers design a brain normalizing system to eliminate reactive oxygen species (ROS) and reeducate microglia from an early phase of AD. Through its efficient neuroprotection and microglia modulatory functions, decreased Aβ plaque burdens and improved cognition are achieved. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
20. Effect and Mechanism of Exogenous Melatonin on Cognitive Deficits in Animal Models of Alzheimer's Disease: A Systematic Review and Meta-analysis.
- Author
-
Zhai, Zhenwei, Xie, Danni, Qin, Tao, Zhong, Yanmei, Xu, Ying, and Sun, Tao
- Subjects
- *
ALZHEIMER'S disease , *ANIMAL models in research , *MELATONIN , *LEARNING ability , *MEMORY disorders - Abstract
• A meta-analysis of melatonin (MT) for interventions of Alzheimer's disease (AD) animal models was conducted. • MT markedly ameliorated learning ability of senescence-related model and metabolic-induced model. • MT corrected memory deficit in the toxin-induced model. • MT reduced amyloid-β levels in AD animal models. Melatonin (MT) has been reported to control and prevent Alzheimer's disease (AD) in the clinic; however, the effect and mechanism of MT on AD have not been specifically described. Therefore, the main purpose of this meta-analysis was to explore the effect and mechanism of MT on AD models by studying behavioural indicators and pathological features. Seven databases were searched and 583 articles were retrieved. Finally, nine studies (13 analyses, 294 animals) were included according to pre-set criteria. Three authors independently judged the selected literature and the methodological quality. Meta-analysis showed that MT markedly ameliorated the learning ability by reducing the escape latency, and the memory deficit was significantly corrected by increasing the dwell time in the target quadrant and crossings over the platform location in the Morris Water Maze (MWM). Among the pathological features, subgroup analysis found that MT may ease the symptoms of AD mainly by reducing the deposition of Aβ 40 and Aβ 42 in the cortex. In addition, MT exerted a superior effect on ameliorating the learning ability of senescence-related and metabolic AD models, and corrected the memory deficit of the toxin-induced AD model. The study was registered at PROSPERO (CRD42021226594). [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
21. Water extract of moschus alleviates erastin-induced ferroptosis by regulating the Keap1/Nrf2 pathway in HT22 cells.
- Author
-
Song, Caiyou, Chu, Zhili, Dai, Jingyi, Xie, Danni, Qin, Tao, Xie, Linjiang, Zhai, Zhenwei, Huang, Sha, Xu, Ying, and Sun, Tao
- Subjects
- *
IRON metabolism , *NEUROPROTECTIVE agents , *GLUTATHIONE , *PROTEINS , *ALZHEIMER'S disease , *NEURONS , *CELLULAR signal transduction , *REACTIVE oxygen species , *LIPID peroxidation (Biology) , *CELL death , *MAMMALS , *WESTERN immunoblotting , *TISSUE extracts , *GLUTATHIONE peroxidase , *CELL survival , *MALONDIALDEHYDE , *CELL receptors , *PHARMACODYNAMICS - Abstract
Moschus, first described in the Shennong's Classic of the Materia medicine, is a scarce and precious animal medicine. Modern pharmacological researches have suggested that Moschus has neuroprotective actions, and its mechanism is related to anti-inflammatory, antioxidant, and anti-apoptosis effects. Ferroptosis is one of the major pathologies of Alzheimer's disease (AD) and is widely implicated in the pathogenesis and progression of AD. Although previous studies have suggested that Moschus possesses neuroprotective effect, whether Moschus could mitigate neuronal damages by inhibiting the onset of ferroptosis is unknown in model cells of AD. The aim of study was to explore the water extract of Moschus (WEM) on ferroptosis caused by erastin and the potential mechanism. Erastin was used to stimulate HT22 cells to form ferroptosis model to evaluate the anti-ferroptosis effect of WEM by cell counting kit-8 and lactic dehydrogenase (LDH) tests. The malondialdehyde (MDA) and glutathione (GSH) kits are used for detection of MDA and GSH levels, and 2′,7′-dichlorofluorescein diacetate and C11 BODIPY 581/591 fluorescence probe are used for evaluation of reactive oxygen species (ROS) and lipid peroxide (LOOH) levels. And Western blot was used to test nuclear factor erythroid 2-related factor 2 (Nrf2), Kelch-like ECH-associated protein 1 (Keap1), heme oxygenase-1 (HO-1), and ferroptosis associated proteins including glutathione peroxidase 4 (GPX4), cystine/glutamate antiporter subunit (SLC7A11), ferritin heavy chain 1 (FTH1), ferroportin1 (FPN1), transferrin receptor (TFRC). In addition, the Nrf2 inhibitor ML385 was applied to verify whether WEM prevents erastin-induced ferroptosis by activating the Keap1/Nrf2 pathway. After WEM treatment, erastin-induced HT22 cell survival was significantly elevated, the accumulation of intracellular MDA, ROS, and LOOH were significantly reduced, the level of GSH and expressions of ferroptosis inhibitors GPX4 and SLC7A11 were significantly increased, and iron metabolism-related proteins TFRC, FPN1, and FTH1 were regulated. These effects of WEM are implemented by activating the Keap1/Nrf2 pathway. This study demonstrated that WEM could perform neuroprotective effects by alleviating ferroptosis, verified that WEM treatment of AD can be mediated by the Keap1/Nrf2 pathway, and provided theoretical support for the application of WEM in the treatment of AD. [Display omitted] • Water extract of Moschus (WEM) alleviated erastin-induced cell damage and promoted the cells viability of HT22. • WEM decreased the MDA, ROS, and lipid peroxide levels and restored the GSH level in erastin-induced HT22 cells. • WEM regulated GPX4, SLC7A11, and iron metabolism proteins by activating the Keap1/Nrf2 axis to inhibit ferroptosis. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
22. Age-related changes in hippocampal AD pathology, actin remodeling proteins and spatial memory behavior of male APP/PS1 mice.
- Author
-
Sun, Huan, Liu, Mengying, Sun, Tao, Chen, Yutong, Lan, Zhen, Lian, Biyao, Zhao, Chengjun, Liu, Zhi, Zhang, Jiqiang, and Liu, Yan
- Subjects
- *
MAZE tests , *SPATIAL memory , *SPATIAL behavior , *TRANSGENIC mice , *NEUROFIBRILLARY tangles , *MICE - Abstract
Alzheimer's disease (AD) is the most common form of dementia in the elderly, characterized by amyloid-beta (Aβ) plaques and tau neurofibrillary tangles (NFTs). Synaptic plasticity impairment is one of the early pathological events in AD. Transgenic APP/PS1 mice that overproduce Aβ are one of the most extensively used AD animal models. Many studies have investigated the roles of NTF-related p-Tau, non-amyloidogenic ADAM10, amyloidogenic BACE1, Aβ proteolytic NEP and IDE in certain ages of APP/PS1 mice as well as dendritic spine-related Rictor and Profilin-1 in normal mice, but there are few studies exploring the age-related changes of these molecules in the hippocampus of APP/PS1 mice. Furthermore, current studies regarding when memory impairment occurs in these mice are controversial. Thus, we examined the changes of these molecules in APP/PS1 and control mice using Western blot in mice 2–month-old (2 m) to 10 m of age and behavior changes using the Morris water maze from 4 m to 8 m. The results showed that in APP/PS1 mice, significant changes of hippocampal p-Tau, Aβ, ADAM10, BACE1 and Rictor occurred at 6 m, NEP at 8 m, and IDE and Profilin-1 at 10 m. In control mice, changes of p-Tau, ADAM10, and BACE1 occurred at 8 m and NEP at 10 m, while IDE, Rictor and Profilin-1 remained unchanged. Importantly, the Morris water maze test revealed that spatial memory impairment was detected at 8 m but not 4 or 6 m. The above findings clearly evidence that neurochemical changes overtly precede cognitive dysfunctions in this AD model and provide novel knowledge for a better understanding of the molecular events driving AD. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
23. Exposure to environmental airborne particulate matter caused wide-ranged transcriptional changes and accelerated Alzheimer's-related pathology: A mouse study.
- Author
-
Israel, Liron L., Braubach, Oliver, Shatalova, Ekaterina S., Chepurna, Oksana, Sharma, Sachin, Klymyshyn, Dmytro, Galstyan, Anna, Chiechi, Antonella, Cox, Alysia, Herman, David, Bliss, Bishop, Hasen, Irene, Ting, Amanda, Arechavala, Rebecca, Kleinman, Michael T., Patil, Rameshwar, Holler, Eggehard, Ljubimova, Julia Y., Koronyo-Hamaoui, Maya, and Sun, Tao
- Subjects
- *
PARTICULATE matter , *ALZHEIMER'S disease , *ENVIRONMENTAL exposure , *AIR pollution , *PATHOLOGY - Abstract
Air pollution poses a significant threat to human health, though a clear understanding of its mechanism remains elusive. In this study, we sought to better understand the effects of various sized particulate matter from polluted air on Alzheimer's disease (AD) development using an AD mouse model. We exposed transgenic Alzheimer's mice in their prodromic stage to different sized particulate matter (PM), with filtered clean air as control. After 3 or 6 months of exposure, mouse brains were harvested and analyzed. RNA-seq analysis showed that various PM have differential effects on the brain transcriptome, and these effects seemed to correlate with PM size. Many genes and pathways were affected after PM exposure. Among them, we found a strong activation in mRNA Nonsense Mediated Decay pathway, an inhibition in pathways related to transcription, neurogenesis and survival signaling as well as angiogenesis, and a dramatic downregulation of collagens. Although we did not detect any extracellular Aβ plaques, immunostaining revealed that both intracellular Aβ1–42 and phospho-Tau levels were increased in various PM exposure conditions compared to the clean air control. NanoString GeoMx analysis demonstrated a remarkable activation of immune responses in the PM exposed mouse brain. Surprisingly, our data also indicated a strong activation of various tumor suppressors including RB1, CDKN1A/p21 and CDKN2A/p16. Collectively, our data demonstrated that exposure to airborne PM caused a profound transcriptional dysregulation and accelerated Alzheimer's-related pathology. [Display omitted] • Exposure to particulate matter (PM) led to wide-ranged transcriptional changes in transgenic Alzheimer's (AD) mouse brain. • PM exposure resulted in an abnormal activation of non-sense mediated decay pathway and down-regulation of collagens. • PM exposure accelerated the development of AD-associated pathology including Aβ42 expression and Tau phosphorylation. • PM exposure led to enhanced neuroinflammation and unprecedented activation of several tumor suppressors. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
24. Moschus exerted protective activity against H2O2-induced cell injury in PC12 cells through regulating Nrf-2/ARE signaling pathways.
- Author
-
Xie, Danni, Deng, Ting, Zhai, Zhenwei, Qin, Tao, Song, Caiyou, Xu, Ying, and Sun, Tao
- Subjects
- *
CELLULAR signal transduction , *ALZHEIMER'S disease , *HEME oxygenase , *BRAIN death , *ANIMAL models in research , *CEREBROVASCULAR disease , *COMA - Abstract
The pivotal characteristics of Alzheimer's disease (AD) are irreversible memory loss and progressive cognitive decline, eventually causing death from brain failure. In the various proposed hypotheses of AD, oxidative stress is also regarded as a symbolic pathophysiologic cascade contributing to brain diseases. Using Chinese herbal medicine may be beneficial for treating and preventing AD. As a rare and valuable animal medicine, Moschus possesses antioxidant and antiapoptotic efficacy and is extensively applied for treating unconsciousness, stroke, coma, and cerebrovascular diseases. We aim to evaluate whether Moschus protects PC12 cells from hydrogen peroxide (H 2 O 2)-induced cellular injury. The chemical constituents of Moschus are analyzed by GC-MS assay. The cell viability, reactive oxygen species (ROS) levels, mitochondrial membrane potential (MMP) levels, oxidative stress-related indicators, and apoptotic proteins are determined. Through GC-MS analysis, nineteen active contents were identified. The cell viability loss, lactate dehydrogenase releases, MMP levels, ROS productions, and Malondialdehyde (MDA) activities decreased, and BAX, Caspase-3, and Kelch-like ECH-associated protein 1 expression also significantly down-regulated and heme oxygenase 1, nuclear factor erythroid-2-related factor 2 (Nrf-2), and quinine oxidoreductase 1 expression upregulated after pretreatment of Moschus. The result indicated Moschus has neuroprotective activity in relieving H 2 O 2 -induced cellular damage, and the potential mechanism might be associated with regulating the Nrf-2/ARE signaling pathway. A more in-depth and comprehensive understanding of Moschus in the pathogenesis of AD will provide a fundamental basis for in vivo AD animal model research, which may be able to provide further insights and new targets for AD therapy. [Display omitted] • H2O2 mimics the in vitro AD oxidative injured model. • H2O2 neurotoxicity causes apoptosis and oxidative damage. • The potential mechanism of oxidative damage may be associated with the Nrf-2/ARE signaling pathways. • Moschus possesses efficiency of neuroprotection, anti-apoptotic, and anti-oxidant in H2O2-induced PC12 cells. • Moschus ameliorates H2O2-induced injury in PC12 cells via regulating the Nrf-2/ARE signaling pathway [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
25. Hippocampal overexpression of SGK1 ameliorates spatial memory, rescues Aβ pathology and actin cytoskeleton polymerization in middle-aged APP/PS1 mice.
- Author
-
Lian, Biyao, Liu, Mengying, Lan, Zhen, Sun, Tao, Meng, Zhaoyou, Chang, Qing, Liu, Zhi, Zhang, Jiqiang, and Zhao, Chengjun
- Subjects
- *
SPATIAL memory , *CYTOSKELETON , *MICE , *POLYMERIZATION , *ALZHEIMER'S disease - Abstract
• Decreased SGK1 was detected in the hippocampus of middle-aged APP/PS1 mice. • SGK1 overexpression ameliorated spatial memory impairment of APP/PS1 mice. • SGK1 overexpression altered hippocampal Aβ production, degradation and plaques. • SGK1 overexpression increased CA1 spine density of APP/PS1 mice. • Upregulation of hippocampal SGK1 may be a novel approach against AD. The increasing occurrence and ineffective treatment of Alzheimer's disease (AD) has become one of the major challenges of the world. Limited studies have shown that serum- and glucocorticoid-inducible kinase 1 (SGK1) is involved in spatial memory formation and consolidation, but its role in AD-like spatial memory impairment and the related mechanisms are not clear. In this study, we first examined the age-related changes of SGK1 in the hippocampus of female APP/PS1 (AD) mice. Based on the finding and our previous finding that significant spatial memory impairment was detected in 8-month old AD mice, SGK1-overexpressing AAV (oSGK1) was constructed and injected into the hippocampus of 9-month old AD mice. One month later, the behavior alterations, Aβ production and deposit as well as changes of CA1 spine density and selected actin polymerization remodeling proteins were examined. The results showed that significant decrease of SGK1 was detected in 10-month old AD mice. The spatial memory impairment, the production and deposit of Aβ were reversed by oSGK1. Levels of hippocampal ADAM10 (α-secretase) and IDE (Aβ degradase), actin remodeling related proteins Rictor, Rac1, Cdc42 and Profilin-1 were significantly increased after oSGK1 treatment while hippocampal BACE1 (γ-secretase) and Cofilin remained unchanged. Taken together, our findings demonstrated a pivotal role of SGK1 in the treatment of AD-related memory impairment through upregulation of non- amyloidogenic processing of APP and degradation of Aβ, increase in spine plasticity related proteins, indicating increase in hippocampal SGK1 may be a potent therapeutic target against AD. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.